Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

Researchers observed a decrease in mean HbA1c from baseline to week 52 from 8.20 to 7.05% with efsitora and from 8.28 to 7.08% with glargine. HealthDay News — Once-weekly insulin efsitora alpha ...

ORLANDO -- Putting type 2 diabetes patients on an automated insulin delivery (AID) pump improved glycemic control, the SECURE-T2D pivotal trial showed. Type 2 diabetes patients started on the Omnipod ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 2025 ADA Standards of Care includes updated ...

At the scientific sessions of the American Diabetes Association, multiple studies were presented showing benefits in Type 2 diabetes through a combination of continuous glucose monitoring and ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar ...

New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA granted 510(k) clearance for a tubeless insulin ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...